You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast CancerAlpelisib plus Olaparib for Triple-Negative Breast Cancer
|
|---|---|
| Published in |
Clinical Cancer Research, February 2022
|
| DOI | 10.1158/1078-0432.ccr-21-3045 |
| Pubmed ID | |
| Authors |
Felipe Batalini, Niya Xiong, Nabihah Tayob, Madeline Polak, Julia Eismann, Lewis C. Cantley, Geoffrey I. Shapiro, Viktor Adalsteinsson, Eric P. Winer, Panagiotis A. Konstantinopoulos, Alan D'Andrea, Elizabeth M. Swisher, Ursula A. Matulonis, Gerburg M. Wulf, Erica L. Mayer |
X Demographics
The data shown below were collected from the profiles of 35 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 13 | 37% |
| Italy | 2 | 6% |
| Brazil | 2 | 6% |
| Comoros | 1 | 3% |
| United Kingdom | 1 | 3% |
| Austria | 1 | 3% |
| India | 1 | 3% |
| Japan | 1 | 3% |
| Canada | 1 | 3% |
| Other | 3 | 9% |
| Unknown | 9 | 26% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 19 | 54% |
| Scientists | 8 | 23% |
| Practitioners (doctors, other healthcare professionals) | 7 | 20% |
| Science communicators (journalists, bloggers, editors) | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 49 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Unspecified | 5 | 10% |
| Student > Ph. D. Student | 4 | 8% |
| Student > Bachelor | 4 | 8% |
| Student > Doctoral Student | 4 | 8% |
| Researcher | 3 | 6% |
| Other | 5 | 10% |
| Unknown | 24 | 49% |
| Readers by discipline | Count | As % |
|---|---|---|
| Unspecified | 5 | 10% |
| Biochemistry, Genetics and Molecular Biology | 5 | 10% |
| Medicine and Dentistry | 5 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 8% |
| Engineering | 2 | 4% |
| Other | 3 | 6% |
| Unknown | 25 | 51% |
Attention Score in Context
This research output has an Altmetric Attention Score of 27. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 August 2023.
All research outputs
#1,426,979
of 25,658,139 outputs
Outputs from Clinical Cancer Research
#980
of 13,283 outputs
Outputs of similar age
#35,957
of 525,590 outputs
Outputs of similar age from Clinical Cancer Research
#38
of 211 outputs
Altmetric has tracked 25,658,139 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,283 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.8. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 525,590 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 211 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.